Aerocrine's Portable Asthma Monitor Launched in France, China

Aerocrine AB (Solna, Sweden) has granted Phadia France (Montigny le Bretonneux, France) the right to market and sell Niox Mino on the French market.

Phadia, a company that specializes in allergy diagnostics, already sells Aerocrine products in Spain. Phadia will begin selling Niox Mino on January 1, 2008. Niox Mino is a non-invasive portable device, which monitors asthma treatment by measuring patients' exhaled nitric acid.

In France, about four million people have diagnosed asthma and the prevalence of asthma- like symptoms is even higher--about 15%. "Phadia has an established market position in France in addition to good knowledge of our products.” said Paul de Potocki, CEO of Aerocrine. "We look forward to working together with Phadia to launch Aerocrine's products in France.”

The Chinese registration authority also approved Aerocrine's Niox products and the company has entered into a distribution agreement with Bioson, Inc. (Beijing, China), which includes sales of both Niox and Niox Mino in China.

Aerocrine is a clinically based medical technology corporation that develops improved asthma management and care products. The company markets Niox Flex worldwide and is now marketing Niox Mino, a new generation of handheld asthma devices, in Europe and China. Both products are tailored for rapid, noninvasive control of the inflammatory status in the airways, and may play a critical role for optimized asthma care and disease control.


Related Links:
Aerocrine
Phadia France
Bioson